Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice

Biochemical Pharmacology

Volumn 85, Issue 1, 2013, Pages 81-91

  Irwin, Nigel ^a   Montgomery, Ian A ^a   Moffett, R Charlotte ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Cholecystokinin (CCK); Diabetes; Glucose tolerance; High fat; Insulin sensitivity; ob ob mice; Obesity

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE DERIVATIVE; CHOLECYSTOKININ RECEPTOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUTAMYL GLUTAMINE CHOLECYSTOKININ OCTAPEPTIDE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CELL SIZE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HISTOLOGY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID DIET; LIVER; MALE; MOUSE; MUSCLE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIETARY FATS; EATING; GLUCAGON; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; LIPIDS; MICE; MICE, OBESE; OBESITY; PANCREAS; RECEPTORS, CHOLECYSTOKININ; SINCALIDE;

EID: 84871718802     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.10.008     Document Type: Article

References (37)

1. G.D. Dinsa, Y. Goryakin, E. Fumagalli, and M. Suhrcke Obesity and socioeconomic status in developing countries: a systematic review Obes Rev 2012 [Epub ahead of print]
2. H. Thomas, and S. Agrawal Systematic review of obesity surgery mortality risk score-preoperative risk stratification in bariatric surgery Obes Surg 22 2012 1135 1140
3. N. Irwin, P. Frizelle, I.A. Montgomery, R.C. Moffett, F.P.M. O'Harte, and P.R. Flatt Beneficial effects of the novel choleycystokinin agonist (pGlu-Gln)-CCK-8 in animal models of obesity-diabetes Diabetologia 55 2012 2747 2758
4. J.F. Rehfeld, L. Friis-Hansen, J.P. Goetze, and T.V. Hansen The biology of cholecystokinin and gastrin peptides Curr Top Med Chem 7 2007 1154 1165
5. I. Verbaeys, F. León-Tamariz, H. Pottel, E. Decuypere, Q. Swennen, and M. Cokelaere PEGylated cholecystokinin is more potent in inducing anorexia than conditioned taste aversion in rats Br J Pharmacol 155 2008 417 423
6. A.C. Ivy, and E. Oldberg A hormone mechanism for gallbladder contraction and evacuation Am J Physiol 65 1928 599 613
7. J.F. Rehfeld Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides Acta Physiol (Oxf) 201 2011 405 411
8. A. Heldsinger, G. Grabauskas, I. Song, and C. Owyang Synergistic interaction between leptin and cholecystokinin in the rat nodose ganglia is mediated by PI3K and STAT3 signaling pathways: implications for leptin as a regulator of short term satiety J Biol Chem 286 2011 11707 11715
9. B. Ahrén, M. Pettersson, K. Uvnäs-Moberg, M. Gutniak, and S. Efendic Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man Diabetes Res Clin Pract 13 1991 153 161
10. J.A. Lavine, P.W. Raess, D.S. Stapleton, M.E. Rabaglia, J.I. Suhonen, K.L. Schueler, J.E. Koltes, J.A. Dawson, B.S. Yandell, L.C. Samuelson, M.C. Beinfeld, D.B. Davis, M.K. Hellerstein, M.P. Keller, and A.D. Attie Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival Endocrinology 151 2010 3577 3588
11. T. Vilsbøll, J.J. Holst, and F.K. Knop The spectrum of antidiabetic actions of GLP-1 in patients with diabetes Best Pract Res Clin Endocrinol Metab 23 2009 453 462
12. F.P. O'Harte, M.H. Mooney, C.M. Kelly, and P.R. Flatt Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation Diabetes 47 1998 1619 1624
13. M. Migaud, C. Durieux, J. Viereck, E. Soroca-Lucas, M.C. Fournié-Zaluski, and B.P. Roques The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A Peptides 17 1996 601 607
14. B.D. Kerr, N. Irwin, F.P. O'Harte, C.J. Bailey, P.R. Flatt, and V.A. Gault Fatty acid derivatised analogs of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties Biochem Pharmacol 78 2009 1008 1016
15. C.J. Bailey, P.R. Flatt, and T. Atkins Influence of genetic background and age on the expression of the obese hyperglycemic syndrome in Aston ob/ob mice Int J Obes 6 1982 11 21
16. M.D. Abramoff, P.J. Magelhaes, and S.J. Ram Image processing with image J Biophotonics International 11 2004 36 42
17. P.R. Flatt, and C.J. Bailey Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice Diabetologia 20 1981 573 577
18. 3)GIP improves metabolic status in high-fat-fed mice Diabetes Obes Metab 12 2010 744 751
19. P.L. McClean, N. Irwin, K. Hunter, V.A. Gault, and P.R. Flatt (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy Br J Pharmacol 155 2008 690 701
20. C.M. Lo, A. King, L.C. Samuelson, T.L. Kindel, T. Rider, R.J. Jandacek, H.E. Raybould, S.C. Woods, and P. Tso Cholecystokinin knockout mice are resistant to high-fat diet-induced obesity Gastroenterology 138 2010 1997 2005
21. M.D. Barrachina, V. Martínez, L. Wang, J.Y. Wei, and Y. Taché Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice PNAS 94 1997 10455 10460
22. S. Mineka, and C.T. Snowdon Inconsistency and possible habituation of CCK-induced satiety Physiol Behav 21 1978 65 72
23. J.N. Crawley, and M.C. Beinfeld Rapid development of tolerance to the behavioural actions of cholecystokinin Nature 302 1983 703 706
24. I. Verbaeys, F. León-Tamariz, J. Buyse, E. Decuypere, H. Pottel, and M. Cokelaere Lack of tolerance development with long-term administration of PEGylated cholecystokinin Peptides 30 2009 699 704
25. C.M. Lo, S. Obici, H.H. Dong, M. Haas, D. Lou, D.H. Kim, M. Liu, D. D'Alessio, S.C. Woods, and P. Tso Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice Diabetes 60 2011 2000 2007
26. C. Brøns, C.B. Jensen, H. Storgaard, N.J. Hiscock, A. White, J.S. Appel, S. Jacobsen, E. Nilsson, C.M. Larsen, A. Astrup, B. Quistorff, and A. Vaag Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men J Physiol 587 2009 2387 2397
27. A.M. Habib, P. Richards, L.S. Cairns, G.J. Rogers, C.A. Bannon, H.E. Parker, T.C. Morley, G.S. Yeo, F. Reimann, and F.M. Gribble Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry Endocrinology 153 2012 3054 3065
28. K. Hisadome, F. Reimann, F.M. Gribble, and S. Trapp CCK stimulation of GLP-1 neurons involves α1-adrenoceptor-mediated increase in glutamatergic synaptic inputs Diabetes 60 2011 2701 2709
29. M. Courtney, A. Pfeifer, K. Al-Hasani, E. Gjernes, A. Vieira, N. Ben-Othman, and P. Collombat In vivo conversion of adult α-cells into β-like cells: a new research avenue in the context of type 1 diabetes Diabetes Obes Metab 13 S1 2011 47 52
30. D.J. Drucker Minireview: the glucagon-like peptides Endocrinology 142 2001 521 527
31. J.J. Holst Glucagon and glucagon-like peptides 1 and 2 Results Probl Cell Differ 50 2010 121 135
32. N.M. Whalley, L.E. Pritchard, D.M. Smith, and A. White Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells J Endocrinol 211 2011 99 106
33. R.D. Wideman, S.D. Covey, G.C. Webb, D.J. Drucker, and T.J. Kieffer A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice Diabetes 56 2007 2744 2752
34. A. Pocai, P.E. Carrington, J.R. Adams, M. Wright, G. Eiermann, L. Zhu, X. Du, A. Petrov, M.E. Lassman, G. Jiang, F. Liu, C. Miller, L.M. Tota, G. Zhou, X. Zhang, M.M. Sountis, A. Santoprete, E. Capito', G.G. Chicchi, N. Thornberry, E. Bianchi, A. Pessi, D.J. Marsh, and R. SinhaRoy Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice Diabetes 58 2009 2258 2266
35. M. Kanzaki, and J.E. Pessin Signal integration and the specificity of insulin action Cell Biochem Biophys 35 2001 191 209
36. D.B. West, M.R. Greenwood, K.A. Marshall, and S.C. Woods Lithium chloride, cholecystokinin and meal patterns: evidence that cholecystokinin suppresses meal size in rats without causing malaise Appetite 8 1987 221 227
37. K.G. Hofbauer, J.R. Nicholson, and O. Boss The obesity epidemic: current and future pharmacological treatments Annu Rev Pharmacol Toxicol 47 2007 565 592